Email this article 
Evolution of СD95+-cells in peripheral blood of patients with ovarian cancer in during the combined treatment
- Authors: Kormosh N.G.1, Zabotina T.N.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- Issue: No 1-2 (2013)
- Pages: 83-92
- Section: GYNECOLOGY. TREATMENT
- Published: 21.05.2013
- URL: https://ojrs.abvpress.ru/ojrs/article/view/45
- DOI: https://doi.org/10.17650/1994-4098-2013-0-1-2-83-92
- ID: 45
Cite item
Full Text
Abstract
Paper deals with the content of CD95+-cells in the blood of patients with ovarian cancer and benign tumors. Found that patients with a malignant process and low CD95+-cells before treatment and during chemotherapy have a poor survival. The initial increase in the relative level CD95+- cells has no effect on survival, increasing the relative level CD95+-cells during chemotherapy is associated with poor survival. Concluded that the CD95 can not be a factor in the forecast, but the reaction of the organism to maintain its level within the physiological range in the treatment of ovarian cancer patients can achieve significantly better long-term results.
Keywords
About the authors
N. G. Kormosh
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: nkormosh@hotmail.com
Russian Federation
T. N. Zabotina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
References
Supplementary files
